PROVIPED. t The function of heat shock proteins (HSP) is to chaperone intracellular proteins and peptides generated during protein synthesis and degradation. This includes proteins and peptides encoded and generated by infectious agents and tumor antigens. The immune system has evolved a sophisticated system to monitor necrotic cell death by detecting cell released HSPs via heat shock protein receptors on APC, and to screen HSPs for chaperoned antigenic peptides by cross presenting them to CDS cells. By generation of a secreted form of hsp-gp96 we created a model imitating cell damage and a system for analyzing in vivo the biological effects of hsp-gp96. This.was done by replacing the KDEL ER-retention signal of human gp96 with the Fc portion of lgG1 to generate a fusion protein, gp96-lg. Gp96-lg-transfected tumor cells secrete gp96-lg in vivo and mediate strong, cognate CD8-CTL expansion, cause tumor rejection and generate long term anti-tumor immunity. We show that secreted gp96-lg-associated peptides are approximately one million fold more efficient than native protein in mediating cognate CDS cross-priming. We also show that tumors can orchestrate tolerogenicity via induction of tolerizing chemokines in their micro environment. Secretion of gp96-lg by tumors triggers a switch in chemokine production in the micro- environment from tolerogenic (induced by w.t. tumors) to immunogenic chemokines (induced by gp96- secretion) resulting in DC and NK recruitment and activation.
In specific aim 1 we will analyze which cells in the microenvironment execute this chemokine switch and test the hypothesis that this switch is required for immunogenicity of gp96. B cells inhibit tumor immunity and gp96 induced CDS clonal expansion. In collaboration with project 3, we will study the mechanisms of B cell inhibition of the CDS response. Together with project 2 we will examine how CDS memory cells are regulated by tumor secreted gp96-lg.
In aim 2 we will use the gp96-lg model system to dissect the mechanisms by which established tumors induce immune tolerance and how tolerance can be reversed. We will test the hypothesis that established tumors induce tolerogenic chemokines in their microenvironment.and that the blockade of these chemokines will synergize with tumor rejection by gp96-vaccines. We will also study the effect of B cell depletion in combination with gp96-immunization after bone marrow transplantation, in collaboration with project 3 and 4. We have generated initial data supporting a new paradigm in immunotherapy: Non-immunogenic tumors are ideal targets for vaccine therapy.
In specific aim 3 we plan to further test this hypothesis in patients with terminal non-small cell lung carcinoma (NSCLC). We propose and will test that gp96 vaccines have ideal vaccine properties due to enhancing antigen cross presentation to CDS cells, activation of innate immunity, and creating a Th1 environment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA109094-01A2
Application #
7226409
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (O5))
Project Start
2006-12-01
Project End
2012-03-31
Budget Start
2006-12-01
Budget End
2008-03-31
Support Year
1
Fiscal Year
2007
Total Cost
$419,167
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Wolf, Dietlinde; Barreras, Henry; Bader, Cameron S et al. (2017) Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:757-766
Schwartz, Marc; Zhang, Yu; Rosenblatt, Joseph D (2016) B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer 4:40
McCormack, Ryan M; Lyapichev, Kirill; Olsson, Melissa L et al. (2015) Enteric pathogens deploy cell cycle inhibiting factors to block the bactericidal activity of Perforin-2. Elife 4:
McCormack, Ryan M; de Armas, Lesley R; Shiratsuchi, Motoaki et al. (2015) Perforin-2 is essential for intracellular defense of parenchymal cells and phagocytes against pathogenic bacteria. Elife 4:
Hatfield, Stephen M; Kjaergaard, Jorgen; Lukashev, Dmitriy et al. (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7:277ra30
Newman, Robert G; Dee, Michael J; Malek, Thomas R et al. (2014) Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice. Blood 123:3045-55
Gonzalez, Louis; Strbo, Natasa; Podack, Eckhard R (2013) Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunol Res 57:326-34
McCormack, Ryan; de Armas, Lesley R; Shiratsuchi, Motoaki et al. (2013) Inhibition of intracellular bacterial replication in fibroblasts is dependent on the perforin-like protein (perforin-2) encoded by macrophage-expressed gene 1. J Innate Immun 5:185-94
Fields, K A; McCormack, R; de Armas, L R et al. (2013) Perforin-2 restricts growth of Chlamydia trachomatis in macrophages. Infect Immun 81:3045-54
McCormack, Ryan; de Armas, Lesley; Shiratsuchi, Motoaki et al. (2013) Killing machines: three pore-forming proteins of the immune system. Immunol Res 57:268-78

Showing the most recent 10 out of 32 publications